Pular para o conteúdo principal
Ranking Invest

CVAC - CureVac N.V.

Segmento: HealthcareCureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.

Análise Ranking Invest

Valuation estimado
$ 81.58 Mi
Último Balanço Atualizado: 1T2025

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 646.69 Mi

Dívida Líquida

-$ 400.95 Mi

L4T

$ 180.66 Mi

MM4T

-1623.24%

Indicadores Básicos

ROE

27.94%

Índices de Previsibilidade

Receita Líquida

F0.41

Lucro

C0.43

Margem

D0.57

Índices de Tendência

Receita Líquida

F-8.33

Lucro

C3.62

Margem

D1.34

Índices de Endividamento

DIV/PAT

-0.62

DIV/L4T

-2.22

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.